Literature DB >> 19573312

[Laparoscopic anatomical nerve sparing radical hysterectomy for cervical cancer: a clinical analysis of 37 cases].

Yong Chen1, Yan Li, Hui-cheng Xu, Jun-nan Li, Yu-yan Li, Zhi-qing Liang.   

Abstract

OBJECTIVE: To investigate feasibility of laparoscopic anatomical nerve sparing radical hysterectomy (LANSRH) used for locally advanced cervical cancer treatment and evaluate early recovery of bladder function postoperatively.
METHODS: From October 2006 to September 2007, 37 cervical cancer patients with stage Ib1 to II a underwent LANSRH (LANSRH group) with pelvic lymphadenectomy matched 25 patients with cervical cancer treated by general laparoscopic radical hysterectomy (LRH, LRH group) with pelvic lymphadenectomy. The data of operating time, blood loss, numbers of lymph node, the length of resected vaginal and paracervix tissue were collected and compared. In the mean time, postoperative recovery of bladder function was evaluated.
RESULTS: The laparoscopic anatomic nerve-sparing procedure was performed successfully and safely among all patients. (1) There was no remarkable difference in the following clinical parameters between LANSRH and LRH group: median operating time [(175 +/- 41) min vs. (178 +/- 30) min, P = 0.72], blood loss [(233 +/- 104) ml vs. (218 +/- 77) ml, P = 0.06], numbers of lymph nodes (13 +/- 4 vs. 15 +/- 6, P = 0.16), resected length of paracervix tissue [(3.6 +/- 0.5) cm vs. (3.7 +/- 0.6) cm, P = 0.43], resected length of vaginal tissue [(3.5 +/- 1.0)cm vs. (3.5 +/- 0.8) cm, P = 0.80]. (2) The mean time of the Foley catheter removed was (10.6 +/- 2.7) days (7 - 17 days) in LANSRH group and (17.2 +/- 4.2) days (9 - 25 days) in LRH group (P = 0.02). After Foley catheter removed, 95% (35/37) presented bladder fulfilling sense, 86% (32/37) presented automatic micturition and urination emptying in LANSRH group. However, In LRH group, 88% (22/25) presented bladder fulfilling sense, 76% (19/25) presented automatic micturition and urination emptying. The bladder void function recovery were 68% (25/37) in class 0 and 3% (1/37) in class II in LANSRH group, when compared with 40% (10/25) in class 0 and 12% (3/25) in class II in LRH group, it reached statistical difference (P < 0.05). In the mean time, there was no significant difference in Class I bladder void function recovery, which were 24% (9/37) and 48% (12/25). (3) No surgery complications and blood transfusion were observed in LANSRH and LRH group. Postoperative pathology suggested that no tumor cell invasion occurred in paracervix tissue and lymph nodes. During the range of 11 to 19 months follow-up, all patients were alive without tumor recurrence and metastasis.
CONCLUSION: LANSRH is safe and feasible surgical management for cervical cancer at early stage and would improve the recovery of bladder voiding function postoperatively by sparing anatomical nerve.

Entities:  

Mesh:

Year:  2009        PMID: 19573312

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  4 in total

Review 1.  Lower urinary tract dysfunction after nerve-sparing radical hysterectomy.

Authors:  Fouad Aoun; Roland van Velthoven
Journal:  Int Urogynecol J       Date:  2014-11-29       Impact factor: 2.894

2.  Conventional versus nerve-sparing radical surgery for cervical cancer: a meta-analysis.

Authors:  Hee Seung Kim; Keewon Kim; Seung Bum Ryoo; Joung Hwa Seo; Sang Youn Kim; Ji Won Park; Min A Kim; Kyoung Sup Hong; Chang Wook Jeong; Yong Sang Song
Journal:  J Gynecol Oncol       Date:  2015-04       Impact factor: 4.401

Review 3.  Clinical efficacy and safety of nerve-sparing radical hysterectomy for cervical cancer: a systematic review and meta-analysis.

Authors:  Ying Long; De-Sheng Yao; Xin-Wei Pan; Ting-Yu Ou
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

4.  Cavitron Ultrasonic Surgical Aspirator in Laparoscopic Nerve-Sparing Radical Hysterectomy: A Pilot Study.

Authors:  Min Hao; Zhilian Wang; Fang Wei; Jingfang Wang; Wei Wang; Yi Ping
Journal:  Int J Gynecol Cancer       Date:  2016-03       Impact factor: 3.437

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.